Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 9415 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than March 26, 

2010. 

A. Federal Reserve Bank of Kansas 

City (Dennis Denney, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Platte Valley Bancorp, Inc., to 

become a bank holding company by 

acquiring 100 percent of the voting 

shares of Platte Valley Bank, both of 

North Bend, Nebraska. 

B. Federal Reserve Bank of San 

Francisco (Kenneth Binning, Vice 

President, Applications and 

Enforcement) 101 Market Street, San 

Francisco, California 94105–1579: 

1. Franklin Resources, Inc., San 

Mateo, California; to retain 9.53 percent 

of the voting shares of West Coast 

Bancorp, and thereby indirectly retain 

voting shares of West Coast Bank, both 

of Lake Oswego, Oregon. 

Board of Governors of the Federal Reserve 

System, February 25, 2010. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2010–4227 Filed 3–1–10; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities 

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States. 

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than March 17, 2010. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Northwest Financial Corp., Arnolds 

Park, Iowa; to engage de novo through 

its subsidiary, Northwest Wealth 

Management, LLC, Arnolds Park, Iowa, 

in investment advisory and 

transactional activities, pursuant to 

sections 225.28(b)(6)(i); (b)(6)(ii); 

b)(6)(v); (b)(7)(i); (b)(7)(ii) and (b)(9)(ii), 

all of Regulation Y. 

Board of Governors of the Federal Reserve 

System, February 25, 2010. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2010–4226 Filed 3–1–10; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL MARITIME COMMISSION 

Notice of Hearing Schedule; Passenger 

Vessel Financial Responsibility 

The Commission has established the 

following allotment of time and order of 

presentation for the hearing concerning 

the Commission’s Passenger Vessel 

Financial Responsibility Program. The 

hearing will convene at 10 a.m., March 

3, 2010, in the Commission’s Main 

Hearing Room, Room 100, 800 North 

Capitol Street, NW., Washington, DC 

20573. In the event that additional time 

is needed to hear all participants and 

allow presenters to field questions from 

the Commission, an afternoon session 

will be convened. 

The due date for submitting the 

original and 15 copies of participant’s 

prepared hearing statement is Friday, 

February 26, 2010. All written 

submissions, except for confidential 

business information, will be available 

for public inspection. 

Company Participant(s) Time allotment 

(in minutes) 

American Cruise Lines Inc. ......................................................... Charles A. Robertson, Chairman & Chief Executive Officer ..... 15 

Carnival Corporation & PLC ....................................................... David Bernstein, Senior Vice President & Chief Financial Officer.15 

Crystal Cruises, Inc. .................................................................... Ann G. Miller, Law Offices of Ann G. Miller .............................. 15 

Cruise Lines International Association ....................................... Terry L. Dale, President and CEO, J. Michael Cavanaugh, 

Holland & Knight LLP.

15 

Passenger Vessel Association ................................................... Ed Welch, Legislative Director ................................................... 15 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

9416 Federal Register / Vol. 75, No. 40 / Tuesday, March 2, 2010 / Notices 

Karen V. Gregory, 

Secretary. 

[FR Doc. 2010–4202 Filed 3–1–10; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Advisory Committee Information 

Hotline 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that we have revised the Advisory 

Committee Information Hotline (the 

hotline). The hotline provides the 

public with access to the most current 

information available on FDA advisory 

committee meetings. This notice 

supersedes all previously published 

announcements of FDA’s Advisory 

Committee Information Hotline. 

FOR FURTHER INFORMATION CONTACT: 

Michael F. Ortwerth, Director, Advisory 

Committee Oversight and Management 

Staff (HF–4), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1220. 

SUPPLEMENTARY INFORMATION: The 

Advisory Committee Information 

Hotline can be accessed by dialing 1– 

800–741–8138 or 301–443–0572. The 

advisory committee meeting 

information and information updates 

can also be accessed via FDA’s Advisory 

Committee Internet site at http:// 

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

Each advisory committee is assigned 

a 10-digit number. This 10-digit number 

will appear in each individual notice of 

meeting. The public can obtain 

information about a particular advisory 

committee meeting by using the 

committee’s 10-digit number. 

Information on the hotline is 

preliminary and may change before a 

meeting is actually held. The hotline 

will be updated when such changes are 

made. The following is a list of each 

advisory committee’s 10-digit number to 

be used when accessing the hotline. The 

list has been updated to add the newly 

established advisory committee in the 

Center for Tobacco called the Tobacco 

Products Scientific Advisory 

Committee. 

Advisory Committee 10-Digit Access Number 

OFFICE OF THE COMMISSIONER 

Pediatric Advisory Committee 8732310001 

Risk Communication Advisory Committee 8732112560 

Science Board to the FDA 3014512603 

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH 

Allergenic Products Advisory Committee 3014512388 

Blood Products Advisory Committee 3014519516 

Cellular, Tissue & Gene Therapies Advisory Committee 3014512389 

Transmissible Spongiform Encephalopathies Advisory Committee 3014512392 

Vaccines and Related Biological Products Advisory Committee 3014512391 

CENTER FOR DRUG EVALUATION AND RESEARCH 

Anesthetic and Life Support Drugs Advisory Committee 3014512529 

Anti-Infective Drugs Advisory Committee 3014512530 

Antiviral Drugs Advisory Committee 3014512531 

Arthritis Advisory Committee 3014512532 

Cardiovascular and Renal Drugs Advisory Committee 3014512533 

Dermatologic and Ophthalmic Drugs Advisory Committee 3014512534 

Drug Safety and Risk Management Advisory Committee 3014512535 

Endocrinologic and Metabolic Drugs Advisory Committee 3014512536 

Gastrointestinal Drugs Advisory Committee 3014512538 

Nonprescription Drugs Advisory Committee 3014512541 

Oncologic Drugs Advisory Committee 3014512542 

Peripheral and Central Nervous System Drugs Advisory Committee 3014512543 

Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly 

Advisory Committee for Pharmaceutical Science) 

3014512539 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES